CTIS2023-505239-10-00招募中1 期
Multi-Omics to predict the blood pressure response to antihypertensives - 114516
Stichting Radboud University Medical Center0 个研究点目标入组 96 人开始时间: 2023年6月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age 18 up to and including 75 years at the time of inclusion, 24 hours systolic blood pressure 130-164 (corresponding with grade 1-2 hypertension), without the use of blood pressure lowering agents (at screening for patients without pre-treatment or after 4 week wash-out of antihypertensive medication for subjects using a single antihypertensive agent at screening), Indication for antihypertensive therapy according to the 2023 European Society of Hypertension Guidelines for the management of arterial hypertension, Female patients must be non-lactating and at no risk of pregnancy for one of the following reasons: 1 year postmenopausal, surgically sterile, or willing to use an acceptable method of contraception throughout the trial (oral contraceptives, approved contraceptive implants, long-term injectable contraception, intrauterine devices, or tubal ligation are allowed.), Subject is not treated with antihypertensive drugs or is treated with a single antihypertensive drug
排除标准
- •Treatment with 2 or more antihypertensive drugs < 3 months before inclusion. It is not allowed to stop medication for study purposes in subjects treated with 2 or more anti-hypertensive drugs, Current biliary tract obstruction, Pregnancy, Known diagnosis of secondary hypertension to an identifiable cause other than treated sleep apnea (e.g., hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome, coarctation of the aorta, uncontrolled hyper- or hypothyroidism and intracranial tumor), Life expectancy < 1 year, Known side effect or contra-indication to treatment with calcium channel blcokers, Known side effect or contra-indication to treatment with angiotensin II receptor blockers, Known side effect or contra-indication to treatment with thiazide diuretics, Arm circumference > 46 cm, Sodium level outside reference range at screening visit, Potassium level outside reference range at screening visit, History of severe valvular or structural heart disease (excluding left ventricular hypertrophy), Calcium level outside reference range at screening visit, eGFR < 50 ml/min/1,73m2, Use of VEGF inhibitors, calcineurin inhibitors, glucocorticosteroids, erythropoietin stimulation agents, daily use of NSAID’s, Use of MDMA, methamphetamine, cocaine, Use of glycyrrhetinic acid containing products , i.e. liquorice, specific herbal teas, <4 weeks before inclusion. (If patients are willing to stop the intake of glycyrrhetinic acid containing products for the duration of the trial, they can be rescreened after 4 weeks of stopping glycyrrhetinic acid containing products), Use of potassium containing supplements, Concurrent use of medication or a supplement with significant drug interaction with study medication. Special attention is warranted for amlodipine which is metabolized by Cyp3A4. Subjects using strong inhibitors or inducers of Cyp3A4 are excluded from participation in this trial. A list of strong inhibitors and inducers is provided in Addendum 1 of the protocol. For information on possible drug interactions we refer to the website of Lexi-Interact Online (Lexicomp® Drug Interactions - UpToDate (doctorabad.com): https://doctorabad.com/UpToDate/d/di.htm)., History of myocardial infarction, angina pectoris, History of atrial fibrillation, Use of loop diuretics, History of NYHA class III or IV heart failure or known reduced left ventricular function (ejection fraction (EF) <30%), History of cerebrovascular accident or transient ischemic attack, History of hypertensive crisis, History of liver failure, History of skin cancer, History of gout, Current hyperparathyroidism
研究者
相似试验
招募中
4 期
Multi-Omics to Predict the Blood Pressure Response to AntihypertensivesPrimary HypertensionNCT05917275Radboud University Medical Center96
尚未招募
Unknown
The Potential of esCCO to Predict Blood Pressure Variability during Dental TreatmentDental cariesJPRN-UMIN000048822Tokyo Medical and Dental University200
招募中
不适用
Application of blood pressure variability as an early-warning system for a decline in blood pressure during the dialysisPatients undergoing hemodialysisJPRN-UMIN000024429agoya City University Graduate School of Medical Sciences Department of Cardio-Renal Medicine and Hypertension20
已完成
不适用
Multidisciplinary Study to Verify Blood Pressure Documentation and Response to Titration of Intravenous MedicationsBlood PressureNCT06253780University of Texas Southwestern Medical Center30
已完成
不适用
Does blood pressure level and variability impact on early neurological deterioration after ischemic stroke?Diseases of the nervous systemKCT0000245Seoul National University Bundang Hospital920